Literature DB >> 24998678

Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Matthias Saar1, Hongjuan Zhao2, Rosalie Nolley2, Sarah R Young2, Ilsa Coleman3, Peter S Nelson3, Robert L Vessella4, Donna M Peehl5.   

Abstract

LuCaP serially transplantable xenografts are valuable preclinical models of locally advanced or metastatic prostate cancer. For the first time, we recently succeeded in establishing and serially passaging spheroid cultures of several LuCaP xenografts. Here, we characterized in depth the molecular and cellular phenotype of LuCaP 147 cultures and found faithful retention of the characteristics of the original xenograft, including immunophenotype, genetic fidelity, gene expression profile and responsiveness to androgen. Furthermore, we demonstrated capabilities for high-throughput drug screening and that anti-cancer agents induced cell cycle arrest and apoptosis in spheroid cultures. Finally, we showed that cells formed tumors when re-introduced into mice, providing an authentic in vitro-in vivo preclinical model of a subtype of prostate cancer with a hypermutator phenotype and an SPOP mutation.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Drug testing; Preclinical model; Prostate cancer; SPOP; Spheroids

Mesh:

Substances:

Year:  2014        PMID: 24998678      PMCID: PMC4112013          DOI: 10.1016/j.canlet.2014.06.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  34 in total

1.  Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant.

Authors:  Muriel Affoué dit Faute; Luc Laurent; Dominique Ploton; Marie-France Poupon; Jean-Claude Jardillier; Hélène Bobichon
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

2.  limmaGUI: a graphical user interface for linear modeling of microarray data.

Authors:  James M Wettenhall; Gordon K Smyth
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

Review 3.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 2.

Authors:  R E Sobel; M D Sadar
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

4.  The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.

Authors:  Chang Wook Jeong; Cheol Yong Yoon; Seong Jin Jeong; Sung Kyu Hong; Seok-Soo Byun; Cheol Kwak; Sang Eun Lee
Journal:  Urol Oncol       Date:  2012-04-25       Impact factor: 3.498

Review 5.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

6.  Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features.

Authors:  Akimitsu Takagi; Masatoshi Watanabe; Yasuhisa Ishii; Joji Morita; Yoshifumi Hirokawa; Takeshi Matsuzaki; Taizo Shiraishi
Journal:  Anticancer Res       Date:  2007 Jan-Feb       Impact factor: 2.480

7.  Determination of subcutaneous tumor size in athymic (nude) mice.

Authors:  M M Tomayko; C P Reynolds
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 8.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1.

Authors:  R E Sobel; M D Sadar
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

9.  Engineering tumors with 3D scaffolds.

Authors:  Claudia Fischbach; Ruth Chen; Takuya Matsumoto; Tobias Schmelzle; Joan S Brugge; Peter J Polverini; David J Mooney
Journal:  Nat Methods       Date:  2007-09-02       Impact factor: 28.547

10.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Authors:  M E Taplin; G J Bubley; T D Shuster; M E Frantz; A E Spooner; G K Ogata; H N Keer; S P Balk
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

View more
  10 in total

1.  Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.

Authors:  Maija P Valta; Hongjuan Zhao; Matthias Saar; Johanna Tuomela; Rosalie Nolley; Johannes Linxweiler; Jouko Sandholm; Jaakko Lehtimäki; Pirkko Härkönen; Ilsa Coleman; Peter S Nelson; Eva Corey; Donna M Peehl
Journal:  Clin Exp Metastasis       Date:  2016-02-12       Impact factor: 5.150

Review 2.  Patient-Derived Prostate Cancer: from Basic Science to the Clinic.

Authors:  Gail P Risbridger; Renea A Taylor
Journal:  Horm Cancer       Date:  2016-05-13       Impact factor: 3.869

3.  Rosuvastatin inhibit spheroid formation and epithelial-mesenchymal transition (EMT) in prostate cancer PC-3 cell line.

Authors:  Abdolkhaleg Deezagi; Naser Safari
Journal:  Mol Biol Rep       Date:  2020-10-21       Impact factor: 2.316

4.  Time-lapse imaging assay using the BioStation CT: a sensitive drug-screening method for three-dimensional cell culture.

Authors:  Ruriko Sakamoto; M Mamunur Rahman; Manami Shimomura; Manabu Itoh; Tetsuya Nakatsura
Journal:  Cancer Sci       Date:  2015-05-06       Impact factor: 6.716

5.  Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.

Authors:  Hui Wang; Christopher E Barbieri; Jintang He; Yuqian Gao; Tujin Shi; Chaochao Wu; Athena A Schepmoes; Thomas L Fillmore; Sung-Suk Chae; Dennis Huang; Juan Miguel Mosquera; Wei-Jun Qian; Richard D Smith; Sudhir Srivastava; Jacob Kagan; David G Camp; Karin D Rodland; Mark A Rubin; Tao Liu
Journal:  J Transl Med       Date:  2017-08-15       Impact factor: 5.531

6.  Progression inference for somatic mutations in cancer.

Authors:  Leif E Peterson; Tatiana Kovyrshina
Journal:  Heliyon       Date:  2017-04-11

7.  The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.

Authors:  Yuqian Yan; Jian Ma; Dejie Wang; Dong Lin; Xiaodong Pang; Shangqian Wang; Yu Zhao; Lei Shi; Hui Xue; Yunqian Pan; Jun Zhang; Claes Wahlestedt; Francis J Giles; Yu Chen; Martin E Gleave; Collin C Collins; Dingwei Ye; Yuzhuo Wang; Haojie Huang
Journal:  EMBO Mol Med       Date:  2019-09-26       Impact factor: 12.137

8.  Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.

Authors:  Tiziano Bernasocchi; Geniver El Tekle; Marco Bolis; Azzurra Mutti; Arianna Vallerga; Laura P Brandt; Filippo Spriano; Tanya Svinkina; Marita Zoma; Valentina Ceserani; Anna Rinaldi; Hana Janouskova; Daniela Bossi; Manuela Cavalli; Simone Mosole; Roger Geiger; Ze Dong; Cai-Guang Yang; Domenico Albino; Andrea Rinaldi; Peter Schraml; Simon Linder; Giuseppina M Carbone; Andrea Alimonti; Francesco Bertoni; Holger Moch; Steven A Carr; Wilbert Zwart; Marianna Kruithof-de Julio; Mark A Rubin; Namrata D Udeshi; Jean-Philippe P Theurillat
Journal:  Nat Commun       Date:  2021-02-02       Impact factor: 14.919

9.  SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.

Authors:  Meghan A Rice; Vineet Kumar; Dhanir Tailor; Fernando Jose Garcia-Marques; En-Chi Hsu; Shiqin Liu; Abel Bermudez; Vijayalakshmi Kanchustambham; Vishnu Shankar; Zintis Inde; Busola Ruth Alabi; Arvind Muruganantham; Michelle Shen; Mallesh Pandrala; Rosalie Nolley; Merve Aslan; Ali Ghoochani; Arushi Agarwal; Mark Buckup; Manoj Kumar; Catherine C Going; Donna M Peehl; Scott J Dixon; Richard N Zare; James D Brooks; Sharon J Pitteri; Sanjay V Malhotra; Tanya Stoyanova
Journal:  Cell Rep Med       Date:  2022-02-02

10.  High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.

Authors:  Nicholas Choo; Susanne Ramm; Jennii Luu; Jean M Winter; Luke A Selth; Amy R Dwyer; Mark Frydenberg; Jeremy Grummet; Shahneen Sandhu; Theresa E Hickey; Wayne D Tilley; Renea A Taylor; Gail P Risbridger; Mitchell G Lawrence; Kaylene J Simpson
Journal:  SLAS Discov       Date:  2021-06-11       Impact factor: 3.341

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.